Uncategorized
Post-market analysis of ocriplasmin consistent with pre-market data
NEW ORLEANS — A post-marketing safety evaluation thus far has been consistent with the pre-marketing clinical trial program for ocriplasmin, according to a speaker here. “At the most recent retina meeting, it became clear that there was significant concern among colleagues regarding post-marketing events surrounding ocriplasmin [Jetrea, ThromboGenics],” Paul Hahn, MD, PhD, said at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting. In response to that concern, the American Society of Retina Specialists convened a Therapeutic Surveillance Committee to compile post-marketing data.